c-Myc Oncoprotein(MYC275 + MYC909), CF405S conjugate, 0.1mg/mL [26628-22-8]

Biotium

c-Myc Oncoprotein(MYC275 + MYC909), CF405S conjugate, 0.1mg/mL

9

ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

Research Use Only

Monoclonal

MYC275 MYC909

0.1 mg/ml

Other Conjugate

MYC

MYC proto-oncogene, bHLH transcription factor

avian myelocytomatosis viral oncogene homolog; bHLHe39; class E basic helix-loop-helix protein 39; c-Myc; MRTL; myc proto-oncogene protein; MYCC; myc-related translation/localization regulatory factor; proto-oncogene c-Myc; transcription factor p64; v-myc avian myelocytomatosis viral oncogene homolog; v-myc myelocytomatosis viral oncogene homolog

Mouse

IgG1

Myc proto-oncogene protein

This antibody recognizes a transcription factor of 64-67 kDa, identified as c-myc. This MAb shows no cross-reaction with v-myc. c-myc is involved in the control of cell proliferation and differentiation and is amplified and/or over-expressed in a variety of tumors. Over-expression of c-myc protein occurs frequently in luminal cells of prostate intraepithelial neoplasia as well as in most primary carcinomas and metastatic disease. Rearrangement of the MYC gene is found in 3% to 16% of diffuse large B-cell lymphoma (DLBCLs) and in nearly 100% of Burkitt lymphomas (BL). Identifying MYC status is important in establishing final diagnosis of DLBCL, BL, or B-cell lymphoma, with features intermediate between DLBCL and BL as well as in differential diagnoses of the lymphomas.

Animal

Bovine, Human, Mouse

2°C to 8°C

12352203